Epithelial lining fluid penetration of temocillin administered by continuous infusion in critically ill patients with nosocomial pneumonia. Visée C.1a,

Slides:



Advertisements
Similar presentations
POPULATION PHARMACOKINETICS OF CEFTRIAXONE IN INTENSIVE CARE UNIT (ICU) ADULT PATIENTS C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte.
Advertisements

Pharmacokinetics Questions
25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.
INTRAVENOUS INFUSION.
Multiple dosing: intravenous bolus administration
Introduction: Temocillin (TMO) is a narrow spectrum penicillin with good activity against Gram negative micro-organisms including ESBL and AmpC producers.
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
Pk/Pd modelling : Clinical Implications
Lecture 2 Clearance, maintenance dose and AUC
Background and Objectives Methods
Isabelle K. Delattre, Françoise Van Bambeke and Paul M. Tulkens
Setting-up a model of intracellular infection by Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. J. Buyck1, O. Jolois2,
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Activities of Daptomycin (DAP), Vancomycin (VAN) and Linezolid (LDZ) alone or in combination with Fusidic acid (FUS) in an in vitro dynamic model of.
A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm.
Activity of tobramycin in combination with clarithromycin
Introduction Results Aim of the study Methods References Conclusion
Optimisation of therapy in Gram-negative infections: TEMOCILLIN
Introduction Results Aim of the study Methods Conclusion References
Temocillin pharmacokinetics in healthy volunteers
Vancomycin administered by continuous infusion should be dosed according to clearance and not based on the patient's body weight P. M. Tulkens1, P. Wallemacq1.
In vitro susceptibility of S
Activity of 9 antibiotics against intracellular forms of S. pneumoniae
Expression of Efflux system
Pharmacokinetics of Old and New Glycopeptides
P 166 Introduction Description of the analyzed population
8th International symposium on Antibiotic and Resistance,
Can efflux confer high levels resistance to meropenem (MEM) in Pseudomonas aeruginosa (Pa) clinical isolates? H. Chalhoub1, H. Rodriguez-Villalobos2,
Introduction & Purpose Results Conclusions
1/06/2018 Development and validation of a HPLC Assay for the Determination of Temocillin in Serum of Haemodialysis Patients A.Bastos1,2, S.Vandecasteele3,
FUS, VAN and LZD injected twice (T0 and T12); DAP injected once (T0).
This poster will be made available for download after the meeting at :
The aminoglycoside antibiotics
Introduction Results Aim Methods References Conclusion
Co-medications Improve Moxifloxacin (MXF) Activity in Models of Pneumococcal Naïve and Induced Biofilms (BF) N. M. Vandevelde1, M. Van Obbergh1, P.M. Tulkens1,
Background and objectives
Comparative in vitro activity of temocillin and other β-lactams
Mapping French population [1]
18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Barcelona, Spain, April 2008 Oral presentation O249 – Sunday April.
Are Vitek2 system and E-test relevant and reliable for determining susceptibility to temocillin? Visée C.1, Frippiat F1, Descy J.2, Meex C.2, Melin P.2,
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Extracellular activity Intracellular activity
Adapted from Jason Sello , Brown university, 2011
Abstract Results Methods Background Conclusions References
29 Vancomycin Administered by Continuous Infusion
PKPD breakpoint (mg/L) PKPD breakpoint (mg/L)
The machine and its calibration
Of a Pig-related ST-398 Methicillin-Resistant S. aureus (A-MRSA)
EV0626 Cellular pharmacokinetics of gepotidacin (GSK )
P-26 ESCMID Conference October 2014, Vienna Austria
Abstract Results Aim of the study Methods Background Conclusions
Difference log CFU from time 0
Total Clearance (CLbody+CLdialysis)
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.
Introduction Results Materials and Methods Conclusions
1200 Brussels - Belgium Temocillin is not substrate for OprD2 porin from Pseudomonas aeruginosa H. Chalhoub1,
Electron microscopy: intracellular infection of THP-1 by S. aureus
Susceptibility of Pseudomonas aeruginosa (P. a
Doripenem vs Meropenem: a summary of International and Belgian published data Françoise Van Bambeke, Unité de Pharmacologie cellulaire et moléculaire Louvain.
P1257 Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection KE Bowker, AR Noel, SG Tomaselli, MLG Attwood, AP.
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy 
Intracellular models of infection to evaluate antibiotic activity
A. Domínguez-Gil Hurlé, A. Sánchez Navarro, M.J. García Sánchez 
Setting-up of a 24 h model to evaluate the activity of antibiotics against intracellular forms of S. aureus infection C. Seral, M. Barcia-Macay, F. Van.
M.R. Jacobs  Clinical Microbiology and Infection 
Grepafloxacin: pharmacokinetics and tissue penetration
Figure 1. CONSORT flow diagram
Université catholique de Louvain, Brussels, Belgium
Presentation transcript:

Epithelial lining fluid penetration of temocillin administered by continuous infusion in critically ill patients with nosocomial pneumonia. Visée C.1a, Layios N.2a, Mistretta V.3, Maes N.4, Van Bambeke F.5, Frippiat F1 1 Infectious diseases, University Hospital of Liège; Liège, Belgium; Contact: clotilde.visee@hotmail.com 2 Intensive care, University Hospital of Liège; Liège, Belgium 3 Toxicology, University Hospital of Liège; Liège, Belgium 4 Biostatistics, University Hospital of Liège; Liège, Belgium 5 Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium a Contributed equally to this work EP0353 Background Results Temocillin is a β-lactam increasingly used in serious infections caused by Enterobacteriaceae, including ESBLs and even some carbapenemase-producing strains, as an alternative to carbapenems, especially in critically ill patients (1-5) . Temocillin is licensed in UK, France, and Belgium for lower respiratory tract infections although clinical data are scarce and no data about Epithelial Lining Fluid (ELF) concentrations are available. Samplings were performed at mean (± SD) 33.2 ± 22.8 hours after the start of CI. The mean (± SD) creatinine clearance based on 24h urine was 112.2 ± 40.7 ml/min/1.73m2, including 3 patients with value > 120 ml/min/1.73 m2 and 1 patient receiving CVVH. Total and free temocillin concentrations and AUC in both plasma and ELF and their respective ELF/plasma ratios are presented in Table 1. A high pharmacokinetic interindividual variability was observed in plasma and ELF for both total and free concentrations but these concentrations remained stable intraindividualy in plasma such as illustrated in Figure 1. Objective We aim to determine serum and ELF temocillin concentrations administered by continuous infusion (CI) in critically ill patients with nosocomial pneumonia. Table 1.   Plasma (mean ± SE) ELF ELF/plasma ratio Total temocillin concentration (mg/L) 68.0 ± 11.3 9.8 ± 1.3 0.17 ± 0.03 Free temocillin concentration (mg/L) 17.3 ± 4.8 9.8 ± 1.6 0.84 ± 0.18 AUC0-24 (mg.h/L) Total temocillin 1632  235  0.14  Free temocillin 415 235 0.57  Material/methods 10 adult patients with severe bacteriologically documented nosocomial pneumonia occuring in ICU were prospectively enrolled and received CI of 6g/day of temocillin after a 30-min 2g loading dose. Plasma and ELF samples were obtained at steady-state and total and free concentrations of temocillin were measured by UHPLC-MS/MS method. Concerning the determination of free temocillin concentrations, an ultracentrifugation prior to UHPLC-MS/MS method was performed (6) . Timing of serial plasma and unique ELF samplings (n = 10) per patient was as follow: Figure 1. (●) ELF concentrations: one sample per patient (─) Plasma concentrations: three samples per patient Conclusions The administration of 6g per day of temocillin by continuous infusion in critically patients with severe nosocomial pneumonia allows a penetration ratio, measured by the ELF/plasma ratio of AUCs, of 0.14 and 0.57 and a mean (± SE) ELF concentration , in mg/L, of 9.8 ± 1.3 and 9.8 ± 1.6 for total and free drug, respectively. Standard error of AUCs should be calculated by the Bootstrap method and Monte Carlo simulations should be performed for subsequent PK/PD analysis. Acknowledgements: This work was supported by Fonds d‘Investissement pour la Recherche Scientifique de l‘hôpital universitaire de Liège (F.I.R.S)). References: 1 Laterre P.-F. and al. JAC 2015; 70: 891–898; 2 Livermore DM, Tulkens PM, JAC. 2009 Feb;63(2):243-245 3 Gupta ND and al. JAC 2009 Aug;64(2):431-433; 4 Balakrishnan I. and al. JAC. 2011 Nov;66(11):2628-31; 5 De Jongh R. and al, JAC 2008 ; 61, 382–388; 6 Ngougni Pokem P., Capron A.. Clin Biochem. 2015 May, 48 (7-8): 542-5